Post by Sanofi Flu HCP

Please see Full Prescribing Information at Flublok (https://lnkd.in/emV7mYAE) and Fluzone High-Dose (https://lnkd.in/ePeZPd2R) INDICATION  Flublok and Fluzone High-Dose are vaccines indicated for active  immunization for the prevention of disease caused by influenza A  virus subtypes and type B virus contained in (or in the case of  Flublok, represented by antigens contained in) the vaccine. Flublok  is approved for use in individuals 9 years of age and older. Fluzone  High-Dose is approved for use in persons 65 years of age and older. IMPORTANT SAFETY INFORMATION  Do not administer Flublok or Fluzone High-Dose to anyone with a  history of a severe allergic reaction (e.g., anaphylaxis) to any  component of the vaccine (including egg protein for Fluzone High-  Dose). Fluzone High-Dose should not be administered to anyone  who has had a severe allergic reaction after previous dose of any  influenza vaccine. Appropriate medical treatment must be immediately available to  manage potential anaphylactic reactions following administration  of the vaccine. If Guillain-Barré syndrome has occurred within 6 weeks following  previous influenza vaccination, the decision to give Flublok or  Fluzone High-Dose should be based on careful consideration of the  potential benefits and risks. If Flublok or Fluzone High-Dose are administered to  immunocompromised persons, including those receiving  immunosuppressive therapy, the expected immune response  may not be attained. Vaccination with Flublok or Fluzone High-Dose may not protect all  recipients. Syncope (fainting) has been reported following vaccination with  Flublok and Fluzone High-Dose. Procedures should be in place to  avoid injury from fainting. For Flublok, in children 9 through 17 years of age who received  Flublok Quadrivalent, the most common solicited injection-site  adverse reaction was pain; the most common solicited systemic  adverse reactions were myalgia, headache, and malaise. In adults  18 through 64 years of age who received Flublok, the most common  injection site adverse reaction was pain; the most common solicited  systemic adverse reactions were headache, fatigue, and myalgia.  In adults 65 years of age and older who received Flublok, the most  common injection-site adverse reaction was pain; the most common  solicited systemic adverse reactions were fatigue and headache.  For Fluzone High-Dose, in adults 65 years of age and older, the most common injection-site reaction was pain; the most common solicited  systemic adverse reactions were myalgia, malaise, and headache.  For Flublok and Fluzone High-Dose, other adverse reactions may  occur.